Dianthus Therapeutics, Inc. (DNTH)
NasdaqCM · USD · Healthcare · Biotechnology
$79.33 (+3.32%) as of
Key statistics
- Market cap
- 4.44B
- Forward P/E
- -17.20
- EPS (TTM)
- -4.24
- Dividend yield
- 0.00%
- 52-week range
- 32.28 – 117.88
- Beta
- 0.18
- Revenue (TTM)
- 1.9M
- Profit margin
- 0.00%
- Analyst target
- $140.80
- Volume
- 501.03k
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, NY, United States
- Employees
- 92
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.